Orforglipron led to 11.5% placebo-adjusted weight loss at 72 weeks (among those who adhered to high-dose treatment) in Attain-1, versus 13.9% at 64 weeks in Oasis 4 for the 25-mg dose of oral ...

The week-ending August 8 saw 20 companies in the healthcare sector report their quarterly earnings. With the earnings season ...

If the plan pans out, it would be an enormous boon to Eli Lilly and Novo Nordisk. Currently, many health insurance plans, as ...

Americans are flocking to new weight loss medications like Novo Nordisk’s Wegovy and Eli Lilly's Zepbound, which work by ...